DaVita HealthCare (DVA) Gains But Lags Market: What You Should Know

18.01.25 00:00 Uhr

Werte in diesem Artikel
Aktien

161,40 EUR 4,20 EUR 2,67%

Indizes

5.996,7 PKT 59,3 PKT 1,00%

DaVita HealthCare (DVA) closed the most recent trading day at $166.24, moving +0.84% from the previous trading session. The stock fell short of the S&P 500, which registered a gain of 1% for the day. On the other hand, the Dow registered a gain of 0.78%, and the technology-centric Nasdaq increased by 1.51%.The kidney dialysis provider's stock has climbed by 11.73% in the past month, exceeding the Medical sector's loss of 1.36% and the S&P 500's loss of 2.14%.Investors will be eagerly watching for the performance of DaVita HealthCare in its upcoming earnings disclosure. On that day, DaVita HealthCare is projected to report earnings of $2.21 per share, which would represent year-over-year growth of 18.18%. Meanwhile, our latest consensus estimate is calling for revenue of $3.25 billion, up 3.47% from the prior-year quarter.It is also important to note the recent changes to analyst estimates for DaVita HealthCare. Such recent modifications usually signify the changing landscape of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. DaVita HealthCare currently has a Zacks Rank of #2 (Buy).With respect to valuation, DaVita HealthCare is currently being traded at a Forward P/E ratio of 14.67. This indicates a discount in contrast to its industry's Forward P/E of 22.14.It's also important to note that DVA currently trades at a PEG ratio of 0.8. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. DVA's industry had an average PEG ratio of 1.93 as of yesterday's close.The Medical - Outpatient and Home Healthcare industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 84, placing it within the top 34% of over 250 industries.The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.Just Released: Zacks Top 10 Stocks for 2025Hurry – you can still get in early on our 10 top tickers for 2025. Handpicked by Zacks Director of Research Sheraz Mian, this portfolio has been stunningly and consistently successful. From inception in 2012 through November, 2024, the Zacks Top 10 Stocks gained +2,112.6%, more than QUADRUPLING the S&P 500’s +475.6%. Sheraz has combed through 4,400 companies covered by the Zacks Rank and handpicked the best 10 to buy and hold in 2025. You can still be among the first to see these just-released stocks with enormous potential. See New Top 10 Stocks >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DaVita Inc. (DVA): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

Ausgewählte Hebelprodukte auf DaVita HealthCare Partners

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf DaVita HealthCare Partners

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu DaVita HealthCare Partners Inc

Wer­bung

Analysen zu DaVita HealthCare Partners Inc

DatumRatingAnalyst
03.01.2019DaVita HealthCare Partners BuyDeutsche Bank AG
14.12.2018DaVita HealthCare Partners OverweightBarclays Capital
12.12.2017DaVita HealthCare Partners OutperformRobert W. Baird & Co. Incorporated
08.11.2017DaVita HealthCare Partners Sector PerformRBC Capital Markets
13.12.2016DaVita HealthCare Partners NeutralRobert W. Baird & Co. Incorporated
DatumRatingAnalyst
03.01.2019DaVita HealthCare Partners BuyDeutsche Bank AG
14.12.2018DaVita HealthCare Partners OverweightBarclays Capital
12.12.2017DaVita HealthCare Partners OutperformRobert W. Baird & Co. Incorporated
27.04.2015DaVita HealthCare Partners OutperformRobert W. Baird & Co. Incorporated
18.10.2011DaVita outperformRobert W. Baird & Co. Incorporated
DatumRatingAnalyst
08.11.2017DaVita HealthCare Partners Sector PerformRBC Capital Markets
13.12.2016DaVita HealthCare Partners NeutralRobert W. Baird & Co. Incorporated
04.11.2015DaVita HealthCare Partners Sector PerformRBC Capital Markets
06.08.2015DaVita HealthCare Partners Sector PerformRBC Capital Markets
13.03.2015DaVita HealthCare Partners HoldDeutsche Bank AG
DatumRatingAnalyst

Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für DaVita HealthCare Partners Inc nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"